Latest Pharma Insights
Strategic Intent: How Circio Rebuilt Itself Around Circular RNA
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026
No Transmitter, No Alerts Without A Phone: Senseonics’ Freedom CGM Trade-Offs
Senseonics has started first-in-human testing of Freedom, a fully transmitter-free implantable CGM that communicates directly with a smartphone — but the device is roughly twice the length of its current sensor and raises unanswered questions about alerts when a phone is unavailable.
Medtech Insight - November 3, 2026
Senseonics has started first-in-human testing of Freedom, a fully transmitter-free implantable CGM that communicates directly with a smartphone — but the device is roughly twice the length of its current sensor and raises unanswered questions about alerts when a phone is unavailable.
Medtech Insight - November 3, 2026
Pulling Oil Rinse Brand Pulls Challenged Claims
GuruNanda challenge leads to Davids Health Sciences withdrawing ad claims. Separately, NAD forwards questions to federal regulators about claims for Red Light brand hat and mask after HigherDose ignores request to support the claims.
HBW Insight - November 3, 2026
GuruNanda challenge leads to Davids Health Sciences withdrawing ad claims. Separately, NAD forwards questions to federal regulators about claims for Red Light brand hat and mask after HigherDose ignores request to support the claims.
HBW Insight - November 3, 2026
Carpe Deodorant Ad Claims For Price Discounts, Superior Performance Sweat Under P&G Challenge
NAD review of advertising for Carpe deodorant should resonate with other start-ups relying on subscription programs as primary sales driver as well as larger businesses, such as P&G, which challenged Carpe claims, as they increasingly offer subscription and direct-to-consumer sales.
HBW Insight - November 3, 2026
NAD review of advertising for Carpe deodorant should resonate with other start-ups relying on subscription programs as primary sales driver as well as larger businesses, such as P&G, which challenged Carpe claims, as they increasingly offer subscription and direct-to-consumer sales.
HBW Insight - November 3, 2026
Inovio Gets Accelerated Approval For Rare HPV-Related Respiratory Disease
Inovio sets a $460,000 list price for a full course of Voceryq, its first approved DNA medicine and the second approved to treat recurrent respiratory papillomatosis.
Scrip - November 2, 2026
Inovio sets a $460,000 list price for a full course of Voceryq, its first approved DNA medicine and the second approved to treat recurrent respiratory papillomatosis.
Scrip - November 2, 2026
LIB Keeps Anti-PCSK9 Pricing Competitive As Lerochol Autoinjector Launch Nears
LIB Therapeutics will launch its autoinjector for once-monthly Lerochol (lerodalcibep), available now in a prefilled syringe, with a $300 monthly list price – the lowest of the PCSK9 inhibitor class.
Scrip - November 2, 2026
LIB Therapeutics will launch its autoinjector for once-monthly Lerochol (lerodalcibep), available now in a prefilled syringe, with a $300 monthly list price – the lowest of the PCSK9 inhibitor class.
Scrip - November 2, 2026
AstraZeneca’s Etcamah Priced In Line With Oral SERD Market
The company declined to publicly disclose the price of the new breast cancer treatment, but the US WAC is $24,392 for a monthly supply, according to a filing with the Vermont Attorney General.
Scrip - November 2, 2026
The company declined to publicly disclose the price of the new breast cancer treatment, but the US WAC is $24,392 for a monthly supply, according to a filing with the Vermont Attorney General.
Scrip - November 2, 2026
In Wake Of Lackluster Trial Results, Karyopharm To Merge With Ayrmid
The company said it would file for bankruptcy under Chapter 11 and merge with the UK-based parent company of Gamida Cell.
Scrip - November 2, 2026
The company said it would file for bankruptcy under Chapter 11 and merge with the UK-based parent company of Gamida Cell.
Scrip - November 2, 2026
ESMO 2026: Where Next For Moderna And Merck’s Cancer Vaccine?
The success of the first Phase III trial of Moderna/Merck & Co.’s intismeran autogene at ESMO has sparked questions over the place of the pioneering individualized vaccine on the melanoma treatment pathway and beyond.
Scrip - November 2, 2026
The success of the first Phase III trial of Moderna/Merck & Co.’s intismeran autogene at ESMO has sparked questions over the place of the pioneering individualized vaccine on the melanoma treatment pathway and beyond.
Scrip - November 2, 2026
Van Naarden On Lilly’s Dealmaking: There’s Plenty More To Come
The company’s head of business development looks back over a remarkably active dealmaking year – and said its less eye-catching transactions might turn out to be the biggest hits.
Scrip - November 2, 2026
The company’s head of business development looks back over a remarkably active dealmaking year – and said its less eye-catching transactions might turn out to be the biggest hits.
Scrip - November 2, 2026
Sun Banks On Unloxcyt’s Keytruda Parity, Ilumya Expansion To Beat Innovation Portfolio Dampening
Sun Pharma is counting on a label expansion for Ilumya, a NCCN upgrade for Unloxcyt in the US and a lerodalcibep license in ex-US and China markets to unlock additional sales.
Scrip - November 2, 2026
Sun Pharma is counting on a label expansion for Ilumya, a NCCN upgrade for Unloxcyt in the US and a lerodalcibep license in ex-US and China markets to unlock additional sales.
Scrip - November 2, 2026
Brainomix Pitches Quantitative CT To Fibrosis Trial Sponsors As Boehringer Partnership Deepens
Brainomix is pitching its e-Lung quantitative CT software to fibrosis trial sponsors after INBUILD data showed it detected nintedanib’s effect, and with Boehringer naming it a co-primary endpoint in the Phase IIIb DROP-FPF trial. FVC remains the regulatory standard.
Scrip - November 2, 2026
Brainomix is pitching its e-Lung quantitative CT software to fibrosis trial sponsors after INBUILD data showed it detected nintedanib’s effect, and with Boehringer naming it a co-primary endpoint in the Phase IIIb DROP-FPF trial. FVC remains the regulatory standard.
Scrip - November 2, 2026
Alzheimer’s And Neurodegeneration Are Forcing System-Wide Change
Earlier detection is reshaping how Alzheimer’s trials are designed and conducted
Scrip - November 2, 2026
Earlier detection is reshaping how Alzheimer’s trials are designed and conducted
Scrip - November 2, 2026
Why Early Evidence Strategy Matters for Emerging Biotechs
Building a stronger evidence strategy to inform development decisions and demonstrate long-term value
Scrip - November 2, 2026
Building a stronger evidence strategy to inform development decisions and demonstrate long-term value
Scrip - November 2, 2026
Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s latest Phase III win.
Scrip - November 2, 2026
In this week's episode: US COINS Act impact; GSK’s oncology turnaround; Lilly’s KRAS push; ris-rez gives new hope in osteosarcoma; and Genmab’s latest Phase III win.
Scrip - November 2, 2026
No Transmitter, No Alerts Without A Phone: Senseonics’ Freedom CGM Trade-Offs
Senseonics has started first-in-human testing of Freedom, a fully transmitter-free implantable CGM that communicates directly with a smartphone — but the device is roughly twice the length of its current sensor and raises unanswered questions about alerts when a phone is unavailable.
Medtech Insight - November 3, 2026
Senseonics has started first-in-human testing of Freedom, a fully transmitter-free implantable CGM that communicates directly with a smartphone — but the device is roughly twice the length of its current sensor and raises unanswered questions about alerts when a phone is unavailable.
Medtech Insight - November 3, 2026
Pulling Oil Rinse Brand Pulls Challenged Claims
GuruNanda challenge leads to Davids Health Sciences withdrawing ad claims. Separately, NAD forwards questions to federal regulators about claims for Red Light brand hat and mask after HigherDose ignores request to support the claims.
HBW Insight - November 3, 2026
GuruNanda challenge leads to Davids Health Sciences withdrawing ad claims. Separately, NAD forwards questions to federal regulators about claims for Red Light brand hat and mask after HigherDose ignores request to support the claims.
HBW Insight - November 3, 2026
Carpe Deodorant Ad Claims For Price Discounts, Superior Performance Sweat Under P&G Challenge
NAD review of advertising for Carpe deodorant should resonate with other start-ups relying on subscription programs as primary sales driver as well as larger businesses, such as P&G, which challenged Carpe claims, as they increasingly offer subscription and direct-to-consumer sales.
HBW Insight - November 3, 2026
NAD review of advertising for Carpe deodorant should resonate with other start-ups relying on subscription programs as primary sales driver as well as larger businesses, such as P&G, which challenged Carpe claims, as they increasingly offer subscription and direct-to-consumer sales.
HBW Insight - November 3, 2026
Sun Expects Organon Acquisition Closure In Q4, India Gains Offset Lenalidomide Slide In Q2
Sun Pharma saw its Q2FY27 US formulation sales decline with falling lenalidomide sales, but the Organon acquisition closure in the fourth quarter, new product launches and continued India business growth are expected to lend support in the second half.
Generics Bulletin - November 2, 2026
Sun Pharma saw its Q2FY27 US formulation sales decline with falling lenalidomide sales, but the Organon acquisition closure in the fourth quarter, new product launches and continued India business growth are expected to lend support in the second half.
Generics Bulletin - November 2, 2026
MS Pharma Partners With Adcan Pharma To Build Biosimilar Resilience In United Arab Emirates
MS Pharma signs a strategic collaboration deal with Adcan Pharma, advancing pharmaceutical localization, especially biosimilars, in United Arab Emirates.
Generics Bulletin - November 2, 2026
MS Pharma signs a strategic collaboration deal with Adcan Pharma, advancing pharmaceutical localization, especially biosimilars, in United Arab Emirates.
Generics Bulletin - November 2, 2026
Fresenius Ups The Ante In Biosimilars With 37-Product WuXi Collaboration
Billed as “the largest development agreement announced in the biosimilars industry to date,” Fresenius Kabi has announced a deal with WuXi Biologics for exclusive option rights for up to 37 “potential first-to-market” biosimilar candidates, more than doubling its existing pipeline.
Generics Bulletin - November 2, 2026
Billed as “the largest development agreement announced in the biosimilars industry to date,” Fresenius Kabi has announced a deal with WuXi Biologics for exclusive option rights for up to 37 “potential first-to-market” biosimilar candidates, more than doubling its existing pipeline.
Generics Bulletin - November 2, 2026
Strategic Intent: How Circio Rebuilt Itself Around Circular RNA
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026
Most biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both.
In Vivo - November 3, 2026